Aurinia Pharmaceuticals Inc.

Aurinia is a biopharmaceutical company that develops and commercializes medical therapies for individuals affected by autoimmune conditions. The company's principal commercial product is voclosporin, branded as Lupkynis, an oral calcineurin inhibitor prescribed for adult patients suffering from active lupus nephritis. Additionally, the company is developing aritinercept, an investigational dual inhibitor targeting cytokines that regulate B-cell activity for autoimmune disorders. In the United States, Aurinia supplies Lupkynis directly to a specialty distributor alongside two specialty pharmacies. For international markets, it provides commercial inventory to its collaboration partner, Otsuka Pharmaceutical, which handles distribution across Europe and Japan.

The organization maintains a workforce of 128 full-time equivalent employees and utilizes external contract manufacturers for drug substance production, capsule encapsulation, and product packaging. Lupkynis holds regulatory approvals and commercial distribution across the United States, Japan, Switzerland, the United Kingdom, and the European Union, with licensing rights extending to additional territories including Norway, Iceland, and Ukraine. The text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Aurinia Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 25, 2026, we had 128 full-time equivalent employees.”